A Pharmacodynamics and Safety Study of DSP-9632P in Patients With Levodopa-Induced Dyskinesia in Parkinson's Disease

NCT05435729 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

7

Enrollment

INDUSTRY

Sponsor class

Conditions

Levodopa-induced Dyskinesia
Parkinson's Disease

Interventions

DRUG: DSP-9632P 27.5 mg
DRUG: DSP-9632P 82.5 mg
DRUG: Placebo
DRUG: DSP-9632P 55.0 mg
DRUG: Levodopa formulation

Sponsor

Sumitomo Pharma Co., Ltd.